Ista Aims To Position Xibrom Using Phase III Dosing, Side Effect Profile; Plans 60-Rep Sales Force
This article was originally published in The Pink Sheet Daily
Executive Summary
The bromfenac ophthalmic formulation did not show evidence of the liver toxicity that caused oral bromfenac (Wyeth’s Duract) to be withdrawn. Ista plans a second quarter NDA filing to treat ocular inflammation post-cataract surgery.